Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?

Abstract: This review article discusses the special role that melatonin, a molecule with chronobiotic/cytoprotective properties, may have in prevention and treatment of the metabolic syndrome (MS), ischemic and non-ischemic cardiovascular diseases and Alzheimer ́...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: ST BIo-Life 2019
Materias:
MELATONINA
ENFERMEDAD DE ALZHEIMER
SINDROME METABOLICO
CRONOBIOLOGIA
ENFERMEDADES CARDIOVASCULARES
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/8811
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139123456789-8811
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic MELATONINA
ENFERMEDAD DE ALZHEIMER
SINDROME METABOLICO
CRONOBIOLOGIA
ENFERMEDADES CARDIOVASCULARES
spellingShingle MELATONINA
ENFERMEDAD DE ALZHEIMER
SINDROME METABOLICO
CRONOBIOLOGIA
ENFERMEDADES CARDIOVASCULARES
Cardinali, Daniel Pedro
Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
topic_facet MELATONINA
ENFERMEDAD DE ALZHEIMER
SINDROME METABOLICO
CRONOBIOLOGIA
ENFERMEDADES CARDIOVASCULARES
description Abstract: This review article discusses the special role that melatonin, a molecule with chronobiotic/cytoprotective properties, may have in prevention and treatment of the metabolic syndrome (MS), ischemic and non-ischemic cardiovascular diseases and Alzheimer ́s disease (AD). Prevention of these diseases is a major goal for governmental and non-governmental organizations, and melatonin, an unusual phylogenetically conserved molecule present in all aerobic organisms, merits consideration in this respect. In humans, circulating melatonin levels are consistently reduced in MS, ischemic and non-ischemic cardiovascular diseases and AD, the potential therapeutic value of melatonin being suggested by a limited number of clinical trials generally employing melatonin in the 2-5 mg/day range. In animal model studies of MS, ischemic and non-ischemic cardiovascular diseases and AD melatonin was very effective to curtail symptomatology. However, calculations derived from animal studies indicate projected cytoprotective melatonin doses for humans in the 40-100 mg/day range, doses that are rarely employed clinically. Hence, controlled studies employing melatonin doses in this range are urgently needed. Since the pharmaceutical industry is refractive to support them because of the lack of protective patents for a natural compound, only the involvement of governmental and non-profit organizations can achieve that goal. Within this prospect, the off-label use of melatonin is discussed.
format Artículo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
author_sort Cardinali, Daniel Pedro
title Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
title_short Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
title_full Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
title_fullStr Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
title_full_unstemmed Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
title_sort are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
publisher ST BIo-Life
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/8811
work_keys_str_mv AT cardinalidanielpedro aremelatonindosesemployedclinicallyadequateformelatonininducedcytoprotection
bdutipo_str Repositorios
_version_ 1764820528565059584

Ejemplares similares